Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jgar.2025.10.019 http://scihub22266oqcxt.onion/10.1016/j.jgar.2025.10.019 41167271!?!41167271 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41167271&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Glob+Antimicrob+Resist 2025 ; 45 (?): 322-328 Nephropedia Template TP {{tp|p=41167271|t=2025. Penetration of Contezolid into bone tissues and body fluids in patients undergoing artificial hip or knee replacement surgery: A prospective cohort study |pdf=|usr=}}{{41167271}} gab.com Text Penetration of Contezolid into bone tissues and body fluids in patients undergoing artificial hip or knee replacement surgery: A prospective cohort study JO: J Glob Antimicrob Resist http://www.kidney.de/pget.php?&tw=1&pmid=41167271 #FOAvip PURPOSE: This study aimed to examine the pharmacokinetic (PK) characteristics and penetration of contezolid into bone tissues and body fluids in patients undergoing artificial hip or knee replacement surgery. METHODS: In a prospective, single center, open label, cohort study, patients received 800 mg contezolid tablets orally, twice a day, for at least two days before surgery. The steady-state PK parameters of contezolid in plasma, body fluids and bone tissues were determined using both noncompartmental analysis (NCA) and population pharmacokinetic (PopPK) modeling. RESULTS: The plasma peak concentration (C(max)) of contezolid was 7.25 +/- 5.27 mg/L in 6 patients undergoing hip replacement surgery, while the corresponding value was 11.46 +/- 6.48 mg/L in 15 patients undergoing knee replacement. The median time to maximum plasma concentration (T(max)) was 1 hour after multiple oral doses of 800 mg contezolid. The ratio of the area under the concentration-time curve of contezolid from 0-12 h (AUC(0-12h,ss)) in tissue to the AUC(0-12h,ss) in plasma was 0.39 to 1.34 in patients undergoing hip replacement surgery, with body fluid-to-plasma AUC(0-12h,ss) ratio was 0.69. In patients undergoing knee replacement, the tissue-to-plasma AUC(0-12h,ss) ratio was 0.12-0.56 and body fluid-to-plasma AUC(0-12h,ss) ratio was 0.51. CONCLUSIONS: The penetration of contezolid into bone and joint tissues can justify the utility of contezolid in managing infections during joint replacement surgery. TRIAL REGISTRATION: http://www.chinadrugtrials.org.cn/ (identifier: CTR20230232?. Twit Text FOAVip Penetration of Contezolid into bone tissues and body fluids in patients undergoing artificial hip or knee replacement surgery: A prospective cohort study ????J Glob Antimicrob Resist http://www.kidney.de/pget.php?&tw=1&pmid=41167271 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=41167271 #FOAvip English Wikipedia <ref>{{Cite pmid|41167271}}</ref> Penetration of Contezolid into bone tissues and body fluids in patients undergoing artificial hip or knee replacement surgery: A prospective cohort study #MMPMID41167271 Yin F; Wu H; Chen Y; Chen Y; Chen M; Guo B; Wang H; Cao Y; Chen T; Zhang J J Glob Antimicrob Resist 2025[Oct]; 45 (?): 322-328 PMID41167271show ga PURPOSE: This study aimed to examine the pharmacokinetic (PK) characteristics and penetration of contezolid into bone tissues and body fluids in patients undergoing artificial hip or knee replacement surgery. METHODS: In a prospective, single center, open label, cohort study, patients received 800 mg contezolid tablets orally, twice a day, for at least two days before surgery. The steady-state PK parameters of contezolid in plasma, body fluids and bone tissues were determined using both noncompartmental analysis (NCA) and population pharmacokinetic (PopPK) modeling. RESULTS: The plasma peak concentration (C(max)) of contezolid was 7.25 +/- 5.27 mg/L in 6 patients undergoing hip replacement surgery, while the corresponding value was 11.46 +/- 6.48 mg/L in 15 patients undergoing knee replacement. The median time to maximum plasma concentration (T(max)) was 1 hour after multiple oral doses of 800 mg contezolid. The ratio of the area under the concentration-time curve of contezolid from 0-12 h (AUC(0-12h,ss)) in tissue to the AUC(0-12h,ss) in plasma was 0.39 to 1.34 in patients undergoing hip replacement surgery, with body fluid-to-plasma AUC(0-12h,ss) ratio was 0.69. In patients undergoing knee replacement, the tissue-to-plasma AUC(0-12h,ss) ratio was 0.12-0.56 and body fluid-to-plasma AUC(0-12h,ss) ratio was 0.51. CONCLUSIONS: The penetration of contezolid into bone and joint tissues can justify the utility of contezolid in managing infections during joint replacement surgery. TRIAL REGISTRATION: http://www.chinadrugtrials.org.cn/ (identifier: CTR20230232?. ?Penetration of Contezolid into bone tissues and body fluids in patient(epmc).pdf DeepDyve Pubget Overpricing